Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15026300 | 1.00 | DGAT1 (0.31) | DGAT1CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL15007529 | 1.00 | DGAT1 (0.31) | DGAT1CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL15031453 | 0.91 | DGAT1 (0.39) | DGAT1CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL15007135 | 0.90 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL15026301 | 0.90 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL15007519 | 0.90 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL16222860 | 0.89 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL41253 | 0.89 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL16229240 | 0.89 | — | — | |
| SCHEMBL16229239 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703784-B2 | Substituted pyrazolo[1,5-a]pyrido[3.2-e]pyrimidin-6-one inhibitors of mammalian target of rapamycin | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130150353-A1 | Fused Tricyclic Inhibitors of Mammalian Target of Rapamycin | MERCK SHARP & DOHME LLC | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150353-A1 | Fused Tricyclic Inhibitors of Mammalian Target of Rapamycin | MTOR, RICTOR, RPTOR | DGAT1 1477/4885CHEK1 1496/4885CCNA2 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.